NCT02944955: An ongoing trial by BioLite, Inc.
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02944955 |
|---|---|
| Title | A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 1, 2026 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 18, 2025 |
| Days late | None |